Compare Repligen Corporation Common Stock (RGEN) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vodafone Group Plc American Depositary Shares — how do they compare? Repligen Corporation Common Stock trades at $184.78 (market cap $11.31B), while Vodafone Group Plc American Depositary Shares trades at $15.88 (market cap $36.16B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 3.2× Repligen Corporation Common Stock's market cap, and Vodafone Group Plc American Depositary Shares pays a 3.46% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vodafone Group Plc American Depositary Shares for 5 Days on average.
| RGEN | VOD | |
|---|---|---|
Market Cap | $11.31B | $36.16B |
Volume | 1,216,919 | 6,634,765 |
Sector | Health | Media |
52-Week High | $194.57 | $17.68 |
52-Week Low | $102.87 | $11.20 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $11.20B | $81.31B |
Dividend Yield | — | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VOD trades at $15.555, up 1.07% today, amid a bearish technical signal. The company reported a net loss of $4.17B for 2025, though revenue grew to $37.45B. Positive cash flow from operations of $15.37B and a low EV/EBITDA of 4.33 suggest underlying value. Recent news highlights Vodafone's strategic focus on 5G rollout and cost synergies in the UK, targeting £1 billion by 2032.
The outlook is mixed; analyst consensus leans buy (48%) with potential from operational improvements, but risks include persistent net losses, high debt, and competitive pressures. The stock's current valuation metrics (P/S 0.82, P/B 0.64) indicate it may be undervalued if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vodafone Group Plc American Depositary Shares
Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.
Read more on VOD →
